## Ethiopia

### Population 2018

- Number: 109 million

### Tuberculosis profile

#### Estimates of TB burden, 2018

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>165 (116–223)</td>
<td>151 (107–204)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>7.6 (5.3–10)</td>
<td>7 (4.9–9.4)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence°°°</td>
<td>1.6 (1–2.2)</td>
<td>1.4 (0.96–2)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>24 (15–36)</td>
<td>22 (14–33)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>2.2 (1.5–3)</td>
<td>2 (1.4–2.8)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 0.71% (0.62–0.8)
- Previously treated cases: 16% (14–17)

#### TB case notifications, 2018

- Total new and relapse: 113,613
  - % tested with rapid diagnostics at time of diagnosis
    - % with known HIV status: 92%
    - % pulmonary: 69%
    - % bacteriologically confirmed°°°: 62%
    - % children aged 0-14 years: 10%
    - % women: 40%
    - % men: 50%

#### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 69% (51–98)
- TB/HIV care in new and relapse TB patients, 2018
  - Number (%) of patients with known HIV status who are HIV-positive
    - on antiretroviral therapy: 4,816 (5%)
    - Total cases notified: 114,233

#### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance°°°
  - New cases: 80%
  - Previously treated cases: 100%

#### Laboratory-confirmed cases*

- MDR/RR-TB: 741, XDR-TB: 3

#### Treatment success rate and cohort size

- New cases registered in 2017: 96% (113,690)
- Previously treated cases registered in 2017
- MDR/RR-TB cases started on second-line treatment in 2016: 72% (703)

#### Treatment success rate (%)

- New cases: 60%
- Previously treated cases: 75%
- MDR/RR-TB: 55%
- XDR-TB: 35%

#### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 49%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 22% (20–24)

#### TB financing, 2019

- National TB budget (US$ millions): 94

- Funding source: 11% domestic, 29% international, 60% unfunded

° Ranges represent uncertainty intervals
°° MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
°°° Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2019-12-15

Data: www.who.int/tb/data